This website or its third-party tools process personal data. You can opt out of the sale of your personal information by clicking on the “Do Not Sell or Share My Personal Information” link.
Powered by
Opt-out Preferences
We use third-party cookies that help us analyse how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. However, you can opt out of these cookies by checking "Do Not Sell or Share My Personal Information" and clicking the "Save My Preferences" button. Once you opt out, you can opt in again at any time by unchecking "Do Not Sell or Share My Personal Information" and clicking the "Save My Preferences" button.
Trelegy Ellipta, by GlaxoSmithKline, is an inhaled medication combining three active ingredients for the once-daily treatment of asthma and chronic obstructive pulmonary disease (COPD), improving lung function, easing breathing difficulties, and reducing flare-ups in patients.
Trelegy Ellipta is an inhaled powder combining corticosteroid, LABA, and LAMA with moderate side effects, manageable interactions, and minimal misuse risk. It requires proper inhaler technique, regular monitoring, and caution in special populations, aligning with FDA safety and usability considerations.
ACNU Feasibility Scorecard
Chart with 11 data points.
Trelegy Ellipta
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying ← Lower is Better!. Data ranges from 1 to 5.
Safety & Risk ProfileSeverity of Side EffectsOverdose PotentialRisk of MisuseDrug-Drug InteractionsSpecial ConsiderationsUsability DifficultyDosing ComplexityMonitoring RequirementsAdherence DifficultyPotential for Tolerance